@NovoNordisk l Corporate Vice President 👉 Corporate Communication l Tweets in DK/ENG l Opinions my own l For media requests, see link below👇" title="" class="btn" data-container="body" data-html="true" data-id="35707" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#b3d4fc" tabindex="0" data-original-title="Katrine Sperling"> 508 222 23,937 199 616 2,059 1,561 45,714 437 1,094 500 2,436 2,233 5,781 2,200,970
Sectors
Location
Bagsværd Torv, 2880 Bagsværd, Denmark
Bagsværd
Denmark
Engaged entities
1412Added in Motherbase
29 Apr 2019, 3:39 p.m.Get updates around our progress and challenges to champion long-term health đź’™ #DrivingChange
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com.
This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam.
Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in:
https://www.novonordisk.com/contact-us/find-local-information.html
For other customer complaints, please contact us here:
https://www.novonordisk.com/contact-us.html
Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed.
Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users.
Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html
Pharmaceuticals, Insulin, obesity, Rare Diseases, and Diabetes
Novo Nordisk | driving change to defeat serious chronic diseases
Entity | Type | Tweets | Articles | |
---|---|---|---|---|
Genomic Expression Inc Biotechnology Research, biotech, deeptech | Other 28 Jan 2025 | | ||
Harvard Office of Technology Development (OTD) Research Services | Other 9 Jan 2025 | | ||
Envisagenics Biotechnology Research, biotech, deeptech | Other 16 Jan 2025 | | ||
Washington Clean Energy Testbeds Renewable Energy Semiconductor Manufacturing, cleantech, energytech | Other 7 Jan 2025 | | ||
Microsoft Cloud Software Development, it services | Other 25 Jan 2025 | | ||
The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School Research Services, healthtech | Other 24 Jan 2025 | | ||
Recursion Biotechnology Research, biotech, deeptech | Other 19 Jan 2025 | | ||
Agora Health healthtech | Other 21 Jan 2025 | | ||
MTC - Medical Training Center - Rouen healthtech, edtech | Other 11 Jan 2025 | | ||
Norges forskningsrĂĄd Government Administration | Other 18 Jan 2025 | |